Spots Global Cancer Trial Database for Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
Official Title: Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis
Study ID: NCT00638391
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Contact Details
Name: H Brasch
Affiliation: AstraZeneca Germany
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
